ESSEX BIO-TECH(01061.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 110.72 million, YoY decrease of 32.24%

NewTimeSpace (newtimespace.com) News, August 05, 2026, ESSEX BIO-TECH(01061.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 784.69 million, decreased by 10.48% YoY; Net Profit stood at HKD 110.72 million, YoY decrease of 32.24%; Profit Attributable to Shareholders stood at HKD 110.72 million, YoY decrease of 32.24%; Basic Earnings Per Share (EPS) stood at HKD 0.2.
In terms of profitability, ESSEX BIO-TECH Gross Profit changed from HKD 778.6 million in the same period last year to HKD 656.26 million in the current period, decreased by HKD 122.34 million; gross profit margin changed from 88.83% in the same period last year to 83.63% in the current period, decreased by 5.19 percentage points; net profit changed from HKD 163.4 million in the same period last year to HKD 110.72 million in the current period, decreased by HKD 52.68 million; net profit margin changed from 18.64% in the same period last year to 14.11% in the current period, decreased by 4.53 percentage points.
In terms of earnings quality, ESSEX BIO-TECH Operating Profit changed from HKD 206.53 million in the same period last year to HKD 152.6 million in the current period, decreased by HKD 53.94 million; Operating Profit Margin changed from 23.56% in the same period last year to 19.45% in the current period, decreased by 4.12 percentage points; Net Cash Flow from Operating Activities changed from cash inflow of HKD 122.49 million in the same period last year to cash inflow of HKD 98.68 million in the current period, decreased by HKD 23.8 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from 13.97% in the same period last year to 12.58% in the current period, decreased by 1.4 percentage points.
In terms of financial soundness, ESSEX BIO-TECH Debt-to-Asset Ratio changed from 29.68% in the same period last year to 29.5% in the current period, decreased by 0.18 percentage points; Total Equity changed from HKD 2.274 billion in the same period last year to HKD 2.549 billion in the current period, increased by HKD 275.44 million; Cash and Cash Equivalents changed from HKD 640.533 million in the same period last year to HKD 806.634 million in the current period, increased by HKD 166.1 million; Current Liabilities changed from HKD 757.81 million in the same period last year to HKD 784.08 million in the current period, increased by HKD 26.27 million; Quick Ratio changed from 1.82 in the same period last year to 2.04 in the current period, increased by 0.22 percentage points.
By the close of trading on August 05, 2026, ESSEX BIO-TECH(01061) saw a loss of 1.66% in its share price, closing at HKD 2.365. The full-day turnover stood at HKD 1.22 million, with the latest market capitalization at HKD 1.34 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.